Seville Universal DXA HealthTeck Startup has earned $ 20 million from the European Investment Bank (EIB) to support the development and commercialization of its blood-based liquid biopsy solutions.
This fund will drive the expansion of Signal-C, its most advanced colorectal cancer screening products, as well as develop new solutions for liver and lung cancer detection (Signal-LI and Signal-Lu, respectively.
Juan Martinez BeriaFounder and President of Universal DX, expressed his enthusiasm for partnerships: “Our goal is to create a future where cancer is curable. With our technology converting forces, we are taking bold steps to make this outlook a reality. We are deeply inspired by EIB’s support, which will enable us to contribute to European plans to fight cancer and bring our revolutionary blood tests to both European and US markets to identify primary cancer. “
Established in 2002, Universal DX is inventing AI-powered computational biology for primary cancer detection. Its platform combines the next generation sequencing (NGS) with the owned biomearker and advanced machine learning algorithm to detect primary cancer signals with high accuracy.
The EIB comes at an important moment to start financial support as it plans to expand in the international market. The next step is to convenience a clinical trial in the United States, FDA approval, which is to facilitate reward and integration in the American health care system.
“We are delighted to join the forces with Universal DX to further specify the initial identification of illness to fight cancer and to improve the survival rate in particular. This financing agreement is another example of how EIB develops innovative European startups to develop breakthrough treatment solutions and support the European Medtech industry“Equity, Growth Capital and Project Finance EIB Director says Alessandro IzoThe
The investment is supported by the Investu Program, whose goal is to combine more than $ 372 billion in strategic investment between 2021 and 2027. The project contributes to strategic priorities in Europe’s defeated cancer plan and advertising of digitalization and technical innovation.
This agreement not only accelerates the expansion of Universal DX but also seems to strengthen Europe’s competition in the biotechnology sector. By combining strategic investment with cutting-edge technology, startup is identifying itself as the original player to make global cancer detection more accessible.
[publish_date
